CLINICAL MANAGEMENT OF METABOLIC PROBLEMS IN PATIENTS WITH SCHIZOPHRENIA:SW

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with schizophrenia have been shown to have more metabolic abnormalities, which are indicators for cardiovascular risk, than their matched controls. Some of the medications used to treat schizophrenia are associated with these metabolic abnormalities. The best treatment strategies for patients with schizophrenia and metabolic risk factors for cardiovascular disease have not yet been established. This study seeks to understand the risks and benefits of switching to a new medication with a low liability of producing metabolic side effects versus staying on a medication with a high liability of producing metabolic side effects.